JP2017535614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535614A5 JP2017535614A5 JP2017545870A JP2017545870A JP2017535614A5 JP 2017535614 A5 JP2017535614 A5 JP 2017535614A5 JP 2017545870 A JP2017545870 A JP 2017545870A JP 2017545870 A JP2017545870 A JP 2017545870A JP 2017535614 A5 JP2017535614 A5 JP 2017535614A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkylene
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 substituted Chemical class 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 24
- 125000002947 alkylene group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- 125000003107 substituted aryl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 102100038495 Bile acid receptor Human genes 0.000 claims 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022171339A JP2023011731A (ja) | 2014-11-21 | 2022-10-26 | 疾患治療用の縮合二環式化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083031P | 2014-11-21 | 2014-11-21 | |
| US62/083,031 | 2014-11-21 | ||
| PCT/US2015/062017 WO2016081918A1 (en) | 2014-11-21 | 2015-11-20 | Fused bicyclic compounds for the treatment of disease |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020125592A Division JP2021011482A (ja) | 2014-11-21 | 2020-07-22 | 疾患治療用の縮合二環式化合物 |
| JP2022171339A Division JP2023011731A (ja) | 2014-11-21 | 2022-10-26 | 疾患治療用の縮合二環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535614A JP2017535614A (ja) | 2017-11-30 |
| JP2017535614A5 true JP2017535614A5 (OSRAM) | 2018-12-27 |
| JP7224102B2 JP7224102B2 (ja) | 2023-02-17 |
Family
ID=56014622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545870A Active JP7224102B2 (ja) | 2014-11-21 | 2015-11-20 | 疾患治療用の縮合二環式化合物 |
| JP2020125592A Pending JP2021011482A (ja) | 2014-11-21 | 2020-07-22 | 疾患治療用の縮合二環式化合物 |
| JP2022171339A Pending JP2023011731A (ja) | 2014-11-21 | 2022-10-26 | 疾患治療用の縮合二環式化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020125592A Pending JP2021011482A (ja) | 2014-11-21 | 2020-07-22 | 疾患治療用の縮合二環式化合物 |
| JP2022171339A Pending JP2023011731A (ja) | 2014-11-21 | 2022-10-26 | 疾患治療用の縮合二環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10233187B2 (OSRAM) |
| EP (1) | EP3221321B1 (OSRAM) |
| JP (3) | JP7224102B2 (OSRAM) |
| KR (1) | KR20170117020A (OSRAM) |
| CN (2) | CN107207513B (OSRAM) |
| AU (2) | AU2015349687B2 (OSRAM) |
| CA (1) | CA2968434A1 (OSRAM) |
| CL (1) | CL2017001289A1 (OSRAM) |
| CO (1) | CO2017005784A2 (OSRAM) |
| ES (1) | ES2911293T3 (OSRAM) |
| IL (1) | IL252309B (OSRAM) |
| MX (1) | MX370480B (OSRAM) |
| MY (1) | MY192927A (OSRAM) |
| RU (1) | RU2706007C2 (OSRAM) |
| SA (1) | SA517381566B1 (OSRAM) |
| SG (2) | SG11201703953WA (OSRAM) |
| WO (1) | WO2016081918A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| MX370480B (es) * | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
| WO2016151403A1 (en) * | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| CA3025007A1 (en) * | 2016-05-25 | 2017-11-30 | Akarna Therapeutics, Ltd. | Combination therapies with farnesoid x receptor (fxr) modulators |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| CA3065313A1 (en) * | 2017-06-02 | 2018-12-06 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds |
| US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| WO2021014350A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Combination treatment of liver diseases using fxr agonists |
| EP4003350A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Treatment comprising fxr agonists |
| EP4025248A1 (en) | 2019-09-03 | 2022-07-13 | Novartis AG | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| EP4031137A1 (en) | 2019-09-19 | 2022-07-27 | Novartis AG | Treatment comprising fxr agonists |
| JP2022550312A (ja) | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| EP4076661A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2023507364A (ja) | 2019-12-20 | 2023-02-22 | ノバルティス アーゲー | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ |
| EP4126875A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| TW202227405A (zh) * | 2020-08-24 | 2022-07-16 | 以色列商安道麥馬克西姆有限公司 | 用於製備經取代的吡唑之方法 |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| BRPI0412262A (pt) | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
| AU2004283196B2 (en) | 2003-09-17 | 2011-08-25 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds |
| US20090137554A1 (en) | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| EP2334681A1 (en) | 2008-09-26 | 2011-06-22 | Wyeth LLC | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| US8252826B2 (en) | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
| MX370480B (es) * | 2014-11-21 | 2019-12-16 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |
| BR112018074231A2 (pt) * | 2016-05-25 | 2019-03-06 | Akarna Therapeutics, Ltd. | compostos bicíclicos fundidos para o tratamento de doença |
-
2015
- 2015-11-20 MX MX2017006694A patent/MX370480B/es active IP Right Grant
- 2015-11-20 EP EP15861717.5A patent/EP3221321B1/en active Active
- 2015-11-20 KR KR1020177016606A patent/KR20170117020A/ko not_active Ceased
- 2015-11-20 AU AU2015349687A patent/AU2015349687B2/en not_active Ceased
- 2015-11-20 RU RU2017121588A patent/RU2706007C2/ru active
- 2015-11-20 WO PCT/US2015/062017 patent/WO2016081918A1/en not_active Ceased
- 2015-11-20 CN CN201580073351.8A patent/CN107207513B/zh not_active Expired - Fee Related
- 2015-11-20 CN CN202010634386.7A patent/CN111662297A/zh active Pending
- 2015-11-20 MY MYPI2017701793A patent/MY192927A/en unknown
- 2015-11-20 ES ES15861717T patent/ES2911293T3/es active Active
- 2015-11-20 CA CA2968434A patent/CA2968434A1/en active Pending
- 2015-11-20 SG SG11201703953WA patent/SG11201703953WA/en unknown
- 2015-11-20 JP JP2017545870A patent/JP7224102B2/ja active Active
- 2015-11-20 SG SG10202010386PA patent/SG10202010386PA/en unknown
-
2017
- 2017-05-16 IL IL252309A patent/IL252309B/en active IP Right Grant
- 2017-05-19 CL CL2017001289A patent/CL2017001289A1/es unknown
- 2017-05-19 US US15/599,647 patent/US10233187B2/en active Active
- 2017-05-20 SA SA517381566A patent/SA517381566B1/ar unknown
- 2017-06-12 CO CONC2017/0005784A patent/CO2017005784A2/es unknown
-
2019
- 2019-03-15 US US16/354,879 patent/US20190308977A1/en not_active Abandoned
-
2020
- 2020-07-22 JP JP2020125592A patent/JP2021011482A/ja active Pending
- 2020-09-18 US US17/025,724 patent/US20210147426A1/en not_active Abandoned
- 2020-10-08 AU AU2020250270A patent/AU2020250270B2/en not_active Ceased
-
2022
- 2022-09-16 US US17/932,876 patent/US20230183247A1/en not_active Abandoned
- 2022-10-26 JP JP2022171339A patent/JP2023011731A/ja active Pending
-
2024
- 2024-06-27 US US18/757,057 patent/US20250171446A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535614A5 (OSRAM) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2015522650A5 (OSRAM) | ||
| JP2016505614A5 (OSRAM) | ||
| JP2015537020A5 (OSRAM) | ||
| JP2016540742A5 (OSRAM) | ||
| JP2017538773A5 (OSRAM) | ||
| JP2016503799A5 (OSRAM) | ||
| JP2016531121A5 (OSRAM) | ||
| JP2017503833A5 (OSRAM) | ||
| JP2016521273A5 (OSRAM) | ||
| JP2017509586A5 (OSRAM) | ||
| JP2017519781A5 (OSRAM) | ||
| JP2016516043A5 (OSRAM) | ||
| JP2016514159A5 (OSRAM) | ||
| JP2015024998A5 (OSRAM) | ||
| JP2015517574A5 (OSRAM) | ||
| JP2012092103A5 (OSRAM) | ||
| JP2014500861A5 (OSRAM) | ||
| JP2017504635A5 (OSRAM) | ||
| JP2018516904A5 (OSRAM) | ||
| JP2015537008A5 (OSRAM) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2017523152A5 (OSRAM) | ||
| RU2020131276A (ru) | Терапевтические соединения и композиции |